Type 2 diabetes
Conditions
Interventions
Active treatment with omarigliptin 25mg/week for 36 months
Sponsors
Department of Diabetes and Metabolism,Tohto Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Type 2 diabetes 2)Diet and exercise are well performed 3)Understanding of the study procedures and consenting to it by signatures
Exclusion criteria
Exclusion criteria: 1)Pregnant or being pregnant within the study 2)Contraindication with Dipeptidyl peptidase 4 inhibitor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose,HbA1c and liver function are set to be measured at baseline and once at 3 months for 36 months. Abdominal ultrasonography is set to be examined at baseline and once at 6 months for 36 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body mass index(BMI),body pressure,immunoreactive insulin(IRI),homeostasis model assessment for insulin resistance(HOMA-IR),high-sensitivity C-reactive protein(hsCRP) and lipid function are set to be measured at baseline and once at 3 months for 36 months. | — |
Countries
Japan
Contacts
Public ContactSachiko Hattori
Foundation Health Medicine Association Tohto Clinic Department of Diabetes and Metabolism
Outcome results
None listed